News - Boehringer Ingelheim, nintedanib

Filter

Popular Filters

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

Boehringer’s nintedanib slows IPF disease progression in Ph III trial

19-05-2014

Results from the Phase III INPULSIS trials, published on-line yesterday in the New England Journal of…

BiotechnologyBoehringer IngelheimnintedanibResearchRespiratory and Pulmonary

Boehringer files for EU approval of nintedanib

Boehringer files for EU approval of nintedanib

15-10-2013

Boehringer Ingelheim has submitted a Marketing Authorization Application to the EMA for the approval…

Boehringer IngelheimEuropenintedanibOncologyPharmaceuticalRegulation

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche

30-09-2013

Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline

02-08-2013

German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta

03-06-2013

Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment

01-11-2012

At its 3rd International Research & Development press conference, family-owned German drug major Boehringer…

afatinibBoehringer IngelheimnintedanibolodaterolOncologyPharmaceuticalProductionResearchRespimatRespiratory and Pulmonary

Analysts view Boehringer Ingelheim's first move into cancer drug market

11-10-2012

German family-owned drug major Boehringer Ingelheim last month announced the submission of a Marketing…

afatinibBoehringer IngelheimMarkets & MarketingnintedanibOncologyPharmaceuticalResearchvolasertib

Back to top